News NICE backs NHS use of Autolus' leukaemia CAR-T Hundreds of people with an aggressive leukaemia will be able to access a CAR-T therapy developed by UK biotech Autolus after a NICE recommendation.
News Autolus closes on EU okay for leukaemia cell therapy The CHMP backed approval of Autolus' leukaemia CAR-T Aucatzyl, as well as drugs from GSK, Roche, SpringWorks, and others, at its May meeting.
News Autolus bags FDA approval for leukaemia cell therapy Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL).
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.